Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5

Molecular Pharmacology

Volumn 84, Issue 3, 2013, Pages 335-345

  Rummel, Pia C ^a   Thiele, Stefanie ^a   Hansen, Lærke S ^a   Petersen, Trine P ^b   Sparre Ulrich, Alexander H ^a   Ulven, Trond ^b   Rosenkilde, Mette M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; DISULFIDE;

ARTICLE; CELL STRAIN COS7; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ANALYSIS;

ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; CHEMOKINE CCL1; CHEMOKINE CCL3; CHEMOKINE CCL5; COS CELLS; DISULFIDES; HUMANS; LIGANDS; MUTAGENESIS, SITE-DIRECTED; PROTEIN FOLDING; RECEPTORS, CCR1; RECEPTORS, CCR5;

EID: 84883155630     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.086702     Document Type: Article

References (60)

1. Ai LS and Liao F (2002) Mutating the four extracellular cysteines in the chemokine receptor CCR6 reveals their differing roles in receptor trafficking, ligand binding, and signaling. Biochemistry 41: 8332-8341.
2. Allen SJ, Crown SE, and Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25: 787-820.
3. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, and Christopoulos A (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282: 25677-25686.
4. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12: 1693-1703.
5. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in Receptor Molecular Biology (Sealfon SC, ed) pp 366-428, Academic Press, New York.
6. Benned-Jensen T, Mokrosinski J, and Rosenkilde MM (2011) The E92K melanocortin 1 receptor mutant induces cAMP production and arrestin recruitment but not ERK activity indicating biased constitutive signaling. PLoS ONE 6:e24644.
7. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, and Kaur R et al. (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46: 4070-4086.
8. Blanpain C, Lee B, Vakili J, Doranz BJ, Govaerts C, Migeotte I, Sharron M, Dupriez V, Vassart G, and Doms RW et al. (1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274: 18902-18908.
9. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee S-L, Saber H, Fourie J, Tornoe C, and Booth B et al. (2010) FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78: 282-288.
10. Chabot DJ, Zhang PF, Quinnan GV, and Broder CC (1999) Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73: 6598-6609.
11. Chen Y, Green SR, Almazan F, and Quehenberger O (2006) The amino terminus and the third extracellular loop of CX3CR1 contain determinants critical for distinct receptor functions. Mol Pharmacol 69: 857-865.
12. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, and Kobilka BK et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
13. Conner M, Hawtin SR, Simms J, Wootten D, Lawson Z, Conner AC, Parslow RA, and Wheatley M (2007) Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-proteincoupled receptor family, identified. J Biol Chem 282: 17405-17412.
14. Cook JVF and Eidne KA (1997) An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. Endocrinology 138: 2800-2806.
15. Davidson FF, Loewen PC, and Khorana HG (1994) Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. Proc Natl Acad Sci USA 91: 4029-4033.
16. de Mendonça FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, and Pease JE (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280: 4808-4816.
17. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, and Allaway GP et al. (1998) Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 72: 279-285.
18. Elling CE, Raffetseder U, Nielsen SM, and Schwartz TW (2000) Disulfide bridge engineering in the tachykinin NK1 receptor. Biochemistry 39: 667-675.
19. Handel TM and Lau EK (2004) Chemokine structure and receptor interaction. Ernst Schering Research Foundation Workshop 45: 101-124.
20. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EYT, Velasquez J, Kuhn P, and Stevens RC (2008) A specific cholesterol binding site is established by the 2.8 A structure of the human b2-adrenergic receptor. Structure 16: 897-905.
21. Herzig MCS, Nash NR, Connolly M, Kyle DJ, and Leeb-Lundberg LMF (1996) The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys20 and Cys277 in the receptor. J Biol Chem 271: 29746-29751.
22. Horuk R (2005) BX471: a CCR1 antagonist with anti-inflammatory activity in man. Mini Rev Med Chem 5: 791-804.
23. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
24. Jensen PC, Nygaard R, Thiele S, Elder A, Zhu G, Kolbeck R, Ghosh S, Schwartz TW, and Rosenkilde MM (2007) Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Mol Pharmacol 72: 327-340.
25. Jensen PC, Thiele S, Steen A, Elder A, Kolbeck R, Ghosh S, Frimurer TM, and Rosenkilde MM (2012) Reversed binding of a small molecule ligand in homologous chemokine receptors-differential role of extracellular loop 2. Br J Pharmacol 166: 258-275.
26. Jensen PC, Thiele S, Ulven T, Schwartz TW, and Rosenkilde MM (2008) Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283: 23121-23128.
27. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, and Durell SR et al. (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274: 9617-9626.
28. Leong SR, Kabakoff RC, and Hébert CA (1994) Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. J Biol Chem 269: 19343-19348.
29. Limatola C, Di Bartolomeo S, Catalano M, Trettel F, Fucile S, Castellani L, and Eusebi F (2005) Cysteine residues are critical for chemokine receptor CXCR2 functional properties. Exp Cell Res 307: 65-75.
30. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, and Arnold GF et al. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281: 12688-12698.
31. Maeda K, Das D, Nakata H, and Mitsuya H (2012) CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs 17: 135-145.
32. Mirzadegan T, Benkö G, Filipek S, and Palczewski K (2003) Sequence analyses of Gprotein- coupled receptors: similarities to rhodopsin. Biochemistry 42: 2759-2767.
33. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
34. Neote K, DiGregorio D, Mak JY, Horuk R, and Schall TJ (1993) Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72: 415-425.
35. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, and Stenkamp RE et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
36. Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, and Marassi FM et al. (2012) Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491: 779-783.
37. Pease JE, Wang J, Ponath PD, and Murphy PM (1998) The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP- 1a and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J Biol Chem 273: 19972-19976.
38. Peeters MC, van Westen GJP, Li Q, and IJzerman AP (2011) Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32: 35-42.
39. Perlman JH, Wang W, Nussenzveig DR, and Gershengorn MC (1995) A disulfide bond between conserved extracellular cysteines in the thyrotropin-releasing hormone receptor is critical for binding. J Biol Chem 270: 24682-24685.
40. Petersen TP, Mirsharghi S, Rummel PC, Thiele S, Rosenkilde MM, Ritzén A, and Ulven T (2013) Multistep continuous-flow synthesis in medicinal chemistry: discovery and preliminary structure-activity relationships of CCR8 ligands. Chemistry DOI: [published ahead of print].
41. Petit SJ, Chayen NE, and Pease JE (2008) Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16. Eur J Immunol 38: 2337-2350.
42. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, and Fischetti RF et al. (2007) Crystal structure of the human b2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
43. Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, and Schwartz TW (2007) Molecular mechanism of action of monocyclam versus bicyclam nonpeptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282: 27354-27365.
44. Rosenkilde MM and Schwartz TW (2006) GluVII:06-a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6: 1319-1333.
45. Rosenkilde MM, Benned-Jensen T, Frimurer TM, and Schwartz TW (2010) The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 31: 567-574.
46. Rossi D and Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
47. Samson M, LaRosa G, Libert F, Paindavoine P, Detheux M, Vassart G, and Parmentier M (1997) The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem 272: 24934-24941.
48. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
49. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5: 434-444.
50. Schwarz MK and Wells TN (2002) New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 1: 347-358.
51. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, Bondy S, Rosen H, and Springer MS (1994) Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 91: 1214-1218.
52. Storjohann L, Holst B, and Schwartz TW (2008) A second disulfide bridge from the Nterminal domain to extracellular loop 2 dampens receptor activity in GPR39. Biochemistry 47: 9198-9207.
53. Thiele S, Malmgaard-Clausen M, Engel-Andreasen J, Steen A, Rummel PC, Nielsen MC, Gloriam DE, Frimurer TM, Ulven T, and RosenkildeMM (2012) Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors. J Med Chem 55: 8164-8177.
54. Thiele S, Steen A, Jensen PC, Mokrosinski J, Frimurer TM, and Rosenkilde MM (2011) Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 286: 37543-37554.
55. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, and Liang M et al. (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281: 27613-27620.
56. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AGW, Tate CG, and Schertler GFX (2008) Structure of a b1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
57. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, and Bi FC et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
58. Xanthou G, Williams TJ, and Pease JE (2003) Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33: 2927-2936.
59. Zeng FY, Soldner A, Schöneberg T, and Wess J (1999) Conserved extracellular cysteine pair in the M3 muscarinic acetylcholine receptor is essential for proper receptor cell surface localization but not for G protein coupling. J Neurochem 72: 2404-2414.
60. Zhang P, Johnson PS, Zöllner C, Wang W, Wang Z, Montes AE, Seidleck BK, Blaschak CJ, and Surratt CK (1999) Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res Mol Brain Res 72: 195-204.